NCT04700618View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Safety and Immunogenicity of PPV23 Vaccine Revaccinated in 60-70 Years Old

PHASE4CompletedINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

March 21, 2021

Primary Completion Date

August 22, 2021

Study Completion Date

February 13, 2022

Conditions
Vaccination
Interventions
BIOLOGICAL

23-valent pneumococcal polysaccharide vaccine

The study group and the control group were vaccinated with one dose of vaccine and blood was collected after 28-40 days.

Trial Locations (1)

Unknown

Shanghai municipal center for disease control and prevention, Shanghai

All Listed Sponsors
collaborator

Shanghai Municipal Center for Disease Control and Prevention

OTHER

lead

China National Biotec Group Company Limited

INDUSTRY

NCT04700618 - A Clinical Trial to Evaluate the Safety and Immunogenicity of PPV23 Vaccine Revaccinated in 60-70 Years Old | Biotech Hunter | Biotech Hunter